CEO Helen Torley exercised options and immediately sold all gains, offsetting 50K shares acquired with 50K disposed—a neutral stake pattern that masks heavy profit-taking.
Helen Torley, President and CEO of HaloZyme, executed a high-volume trading sequence over three days: exercising 50,000 shares at a fixed price and simultaneously selling the same number of shares across twelve separate transactions at prices ranging significantly higher. This is a mechanically neutral net position—her direct stake remained essentially flat at 767,780 shares—but the transaction pattern itself reveals important context. Torley is a serial seller with 104 open-market sales across all her holdings in the trailing 36 months (12 at HaloZyme in this filing alone), and her five prior HaloZyme sales showed mixed timing: three were well-timed exits where the stock subsequently fell, but two were poorly timed as the stock rallied afterward. Over the longer 90-day horizon, all five prior HaloZyme exits proved poorly timed, as the stock gained in every instance. The current exercise-and-sell pattern happens while the stock trades well below its 52-week high and the company shows strong fundamentals—profitable with accelerating revenue growth and a reasonable valuation multiple. Torley's willingness to immediately liquidate every exercised share, combined with her exclusively sell-focused filing history and the mixed historical accuracy of her HaloZyme exits, does not convey insider conviction in the stock's near-term trajectory.